China Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), By Therapeutic Class (Chemotherapy, Immunotherapy), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease type
  • 1.2.2. Therapeutics class
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease type outlook
  • 2.2.2. Therapeutics class outlook
• 2.3. Competitive Insights

Chapter 3. China Lung Cancer Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of lung cancer
    • 3.2.1.2. Aging population
    • 3.2.1.3. Advancements in medical diagnostic equipment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High costs of advanced immunotherapies and targeted therapies
• 3.3. China Lung Cancer Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. China Lung Cancer Therapeutics Market: Disease Type Estimates & Trend Analysis

• 4.1. Disease Type Segment Dashboard
• 4.2. China Lung Cancer Therapeutics Market: Disease Type Movement Analysis
• 4.3. China Lung Cancer Therapeutics Market by Disease Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Non-small Cell Lung Cancer (NSCLC)
  • 4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Small Cell Lung Cancer (SCLC)
  • 4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. China Lung Cancer Therapeutics Market: Therapeutics Class Estimates & Trend Analysis

• 5.1. Therapeutics Class Segment Dashboard
• 5.2. China Lung Cancer Therapeutics Market: Therapeutics Class Movement Analysis
• 5.3. China Lung Cancer Therapeutics Market by Therapeutics Class Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Chemotherapy
  • 5.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Radiation Therapy
  • 5.6.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Immunotherapy
  • 5.7.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Targeted Therapy
  • 5.8.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Other Treatments
  • 5.9.1. Other Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. AstraZeneca
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic initiatives
  • 6.2.2. Roche
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. Pfizer
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Novartis
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Merck & Co.
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Bristol-Myers Squibb
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Eli Lilly and Company
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Boehringer Ingelheim
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Johnson & Johnson (Janssen Pharmaceuticals)
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. BeiGene
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives
  • 6.2.11. Innovent Biologics
    • 6.2.11.1. Company overview
    • 6.2.11.2. Financial performance
    • 6.2.11.3. Product benchmarking
    • 6.2.11.4. Strategic initiatives
  • 6.2.12. Jiangsu Hengrui Medicine Co., Ltd.
    • 6.2.12.1. Company overview
    • 6.2.12.2. Financial performance
    • 6.2.12.3. Product benchmarking
    • 6.2.12.4. Strategic initiatives
  • 6.2.13. China National Pharmaceutical Group (Sinopharm)
    • 6.2.13.1. Company overview
    • 6.2.13.2. Financial performance
    • 6.2.13.3. Product benchmarking
    • 6.2.13.4. Strategic initiatives
  • 6.2.14. Shanghai Junshi Biosciences Co., Ltd.
    • 6.2.14.1. Company overview
    • 6.2.14.2. Financial performance
    • 6.2.14.3. Product benchmarking
    • 6.2.14.4. Strategic initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 China lung cancer therapeutics market, by disease type, 2018 - 2030 (USD Million)
• Table 4 China lung cancer therapeutics market, by therapeutic class, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 China lung cancer therapeutics market segmentation
• Fig. 7 Market driver analysis (Current & future impact)
• Fig. 8 Market restraint analysis (Current & future impact)
• Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 China lung cancer therapeutics market, disease type outlook key takeaways (USD Million)
• Fig. 12 China lung cancer therapeutics market: disease type movement analysis 2023 & 2030 (USD Million)
• Fig. 13 Non-small cell lung cancer (NSCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Small cell lung cancer (SCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 China lung cancer therapeutics market, therapeutic class outlook key takeaways (USD Million)
• Fig. 16 China lung cancer therapeutics market: therapeutic class movement analysis 2023 & 2030 (USD Million)
• Fig. 17 Chemotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Radiation therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Targeted therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Other treatments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 China lung cancer therapeutics Market, end use outlook key takeaways (USD Million)